<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621855</url>
  </required_header>
  <id_info>
    <org_study_id>1160.67</org_study_id>
    <secondary_id>RE-DEEM</secondary_id>
    <secondary_id>2007-004301-99</secondary_id>
    <nct_id>NCT00621855</nct_id>
  </id_info>
  <brief_title>RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome</brief_title>
  <official_title>RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4
      doses of orally administered dabigatran etexilate, administered twice daily, compared to
      placebo when given in addition to dual antiplatelet treatment in patients with an index event
      (MI) at high risk for new ischaemic cardiovascular events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time</measure>
    <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
    <description>International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.
A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.
All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment</measure>
    <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
    <description>Number of Participants with Composite of Cardiovascular death (CVD) with non fatal myocardial infarction (MI) and non haemorrhagic stroke and All cause death (ACD), non fatal MI, severe recurrent ischaemia (SRI) and non haemorrhagic stroke during six months treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment</measure>
    <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
    <description>Number of Participants with individual occurrence of death (cardiovascular and all-cause), non-fatal MI, severe recurrent ischaemia and non-haemorrhagic stroke during six months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Reduction of D-dimer Concentration</measure>
    <time_frame>at 1 week and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in log10 D-dimer After 1 and 4 Weeks</measure>
    <time_frame>Baseline and at 1 week and 4 weeks</time_frame>
    <description>Change from baseline in log10 D-dimer concentration after 1 and 4 weeks of dabigatran etexilate treatment compared to placebo. The standard deviation is the geometric standard deviation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events During Total Observation Time</measure>
    <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
    <description>International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.
A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.
All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds (CRBE) and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
    <description>Number of patients with possible clinically significant abnormalities. Clinically significant abnormalities refers to the increase or decrease from baseline.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1878</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily dosing,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily dosing, patients with moderate renal impairment allocated 50mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 110mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily dosing, patients with moderate renal impairment allocated 75mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran etexilate 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily dosing, patients with moderate renal impairment allocated 110mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>capsules, twice daily, 26 weeks treatment</description>
    <arm_group_label>Dabigatran etexilate 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>capsules, twice daily, 26 weeks treatment</description>
    <arm_group_label>Dabigatran etexilate 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>capsules, twice daily, 26 weeks treatment</description>
    <arm_group_label>Dabigatran etexilate 110mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>capsules, twice daily, 26 weeks treatment</description>
    <arm_group_label>dabigatran etexilate 150mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Patients with acute coronary syndromes with at least one additional risk
        factor for cardiovascular complications.

        Exclusion criteria

          1. Long term treatment with any other oral anticoagulant

          2. Severe/disabling stroke within last 6 months

          3. Conditions associated with increased bleeding risk

          4. Anaemia or thrombocytopenia

          5. Severe renal impairment

          6. Liver disease

          7. Positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.67.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bouge/Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gilly</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tienen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dimitrovgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.59010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Terrebonne</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.11014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Litomerice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.42008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.58001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>HUS</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.58004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.58003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.58002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.95001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.95002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.95003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.95004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.95005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.95006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.53001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.53002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>S. Maria Capua Vetere (CE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejoen</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kwang-Ju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogeveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spijkenisse</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hønefoss</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inowroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.40006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.40007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tg. Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Motala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaesteraas</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivano-Frankovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nikolayev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.67.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>January 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2011</results_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>International multi-centre trial with 161 trial sites in 24 countries recruiting patients with acute coronary syndromes with increased troponin levels within 14 days post index myocardial infarction (ST or non-ST elevation between March 2008 and March 2009.</recruitment_details>
      <pre_assignment_details>Patients receiving aspirin and clopidogrel at randomisation were included. They also had at least 1 additional risk factor (for e.g. age ≥65 years, diabetes previous myocardial infarction, peripheral arterial disease). Moderate renal impairment at screening resulted in dose adjustment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>50mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="P2">
          <title>75mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="P3">
          <title>110mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="P4">
          <title>150mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>26 week blinded treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="372">Started means randomised to treatment</participants>
                <participants group_id="P2" count="371">Started means randomised to treatment</participants>
                <participants group_id="P3" count="411">Started means randomised to treatment</participants>
                <participants group_id="P4" count="351">Started means randomised to treatment</participants>
                <participants group_id="P5" count="373">Started means randomised to treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="296">Completed means completed treatment</participants>
                <participants group_id="P2" count="310">Completed means completed treatment</participants>
                <participants group_id="P3" count="330">Completed means completed treatment</participants>
                <participants group_id="P4" count="284">Completed means completed treatment</participants>
                <participants group_id="P5" count="318">Completed means completed treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patients did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>50mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="B2">
          <title>75mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="B3">
          <title>110mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="B4">
          <title>150mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="372"/>
            <count group_id="B2" value="371"/>
            <count group_id="B3" value="411"/>
            <count group_id="B4" value="351"/>
            <count group_id="B5" value="373"/>
            <count group_id="B6" value="1878"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="12.2"/>
                    <measurement group_id="B2" value="60.7" spread="11.7"/>
                    <measurement group_id="B3" value="62.3" spread="11.1"/>
                    <measurement group_id="B4" value="62.3" spread="10.8"/>
                    <measurement group_id="B5" value="61.5" spread="11.3"/>
                    <measurement group_id="B6" value="61.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="81"/>
                    <measurement group_id="B6" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="294"/>
                    <measurement group_id="B4" value="258"/>
                    <measurement group_id="B5" value="292"/>
                    <measurement group_id="B6" value="1428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="324"/>
                    <measurement group_id="B4" value="300"/>
                    <measurement group_id="B5" value="268"/>
                    <measurement group_id="B6" value="1447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="105"/>
                    <measurement group_id="B6" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Central Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="217"/>
                    <measurement group_id="B5" value="165"/>
                    <measurement group_id="B6" value="932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="84"/>
                    <measurement group_id="B6" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="104"/>
                    <measurement group_id="B6" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Index Event</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ST elevation myocardial infarction (STEMI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="204"/>
                    <measurement group_id="B5" value="230"/>
                    <measurement group_id="B6" value="1126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non ST elevation myocardial infarction (NSTEMI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="147"/>
                    <measurement group_id="B5" value="143"/>
                    <measurement group_id="B6" value="752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine Clearance N=(372;371;411;350;373;1877)</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.4" spread="30.2"/>
                    <measurement group_id="B2" value="88.7" spread="32.4"/>
                    <measurement group_id="B3" value="84.7" spread="32"/>
                    <measurement group_id="B4" value="86.3" spread="28.1"/>
                    <measurement group_id="B5" value="86.6" spread="34.8"/>
                    <measurement group_id="B6" value="86.3" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time</title>
        <description>International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.
A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.
All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).</description>
        <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
        <population>Treated set - The treated set includes all patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O2">
            <title>75mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O3">
            <title>110mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O4">
            <title>150mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>26 week blinded treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time</title>
          <description>International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.
A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.
All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).</description>
          <population>Treated set - The treated set includes all patients who received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="368"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="347"/>
                <count group_id="O5" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major and clinically relevant minor bleed events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No major or clinically relevant minor bleed events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="352"/>
                    <measurement group_id="O3" value="374"/>
                    <measurement group_id="O4" value="320"/>
                    <measurement group_id="O5" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The proportion of patients who reach this endpoint were analysed by a logistic model for linear trend (dose response).
The null hypothesis is that the relationship between dose level (0mg, 50mg, 75mg, 110mg and 150mg) and the proportions of patients with major and clinically relevant minor bleeding is not linear (slope parameter = 0)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Armitage test for linear trend</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment</title>
        <description>Number of Participants with Composite of Cardiovascular death (CVD) with non fatal myocardial infarction (MI) and non haemorrhagic stroke and All cause death (ACD), non fatal MI, severe recurrent ischaemia (SRI) and non haemorrhagic stroke during six months treatment</description>
        <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O2">
            <title>75mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O3">
            <title>110mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O4">
            <title>150mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>26 week blinded treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment</title>
          <description>Number of Participants with Composite of Cardiovascular death (CVD) with non fatal myocardial infarction (MI) and non haemorrhagic stroke and All cause death (ACD), non fatal MI, severe recurrent ischaemia (SRI) and non haemorrhagic stroke during six months treatment</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="368"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="347"/>
                <count group_id="O5" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CVD, non-fatal MI, non-haemorrhagic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACD, non-fatal MI, SRI, non-haemorrhagic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment</title>
        <description>Number of Participants with individual occurrence of death (cardiovascular and all-cause), non-fatal MI, severe recurrent ischaemia and non-haemorrhagic stroke during six months of treatment.</description>
        <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O2">
            <title>75mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O3">
            <title>110mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O4">
            <title>150mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>26 week blinded treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment</title>
          <description>Number of Participants with individual occurrence of death (cardiovascular and all-cause), non-fatal MI, severe recurrent ischaemia and non-haemorrhagic stroke during six months of treatment.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="368"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="347"/>
                <count group_id="O5" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non−fatal myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe recurrent ischaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non−haemorrhagic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All cause death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Reduction of D-dimer Concentration</title>
        <time_frame>at 1 week and 4 weeks</time_frame>
        <population>Full analysis set - The full analysis set includes all randomised and treated patients who had at least one post-dose assessment of D-dimer available.</population>
        <group_list>
          <group group_id="O1">
            <title>50mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O2">
            <title>75mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O3">
            <title>110mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O4">
            <title>150mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>26 week blinded treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Reduction of D-dimer Concentration</title>
          <population>Full analysis set - The full analysis set includes all randomised and treated patients who had at least one post-dose assessment of D-dimer available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="388"/>
                <count group_id="O4" value="332"/>
                <count group_id="O5" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Patients with any reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="293"/>
                    <measurement group_id="O3" value="333"/>
                    <measurement group_id="O4" value="296"/>
                    <measurement group_id="O5" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Patients with no reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The proportion of patients who reach this endpoint were analysed by a logistic model for linear trend (dose response).
The null hypothesis is that the relationship between dose level (0mg, 50mg, 75mg, 110mg and 150mg) and the proportions of patients with major and clinically relevant minor bleeding is not linear (slope parameter = 0)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Armitage test for linear trend</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in log10 D-dimer After 1 and 4 Weeks</title>
        <description>Change from baseline in log10 D-dimer concentration after 1 and 4 weeks of dabigatran etexilate treatment compared to placebo. The standard deviation is the geometric standard deviation.</description>
        <time_frame>Baseline and at 1 week and 4 weeks</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>50mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O2">
            <title>75mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O3">
            <title>110mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O4">
            <title>150mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>26 week blinded treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in log10 D-dimer After 1 and 4 Weeks</title>
          <description>Change from baseline in log10 D-dimer concentration after 1 and 4 weeks of dabigatran etexilate treatment compared to placebo. The standard deviation is the geometric standard deviation.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="388"/>
                <count group_id="O4" value="332"/>
                <count group_id="O5" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ratio of week 4 to baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="3.04"/>
                    <measurement group_id="O2" value="0.31" spread="3.30"/>
                    <measurement group_id="O3" value="0.29" spread="3.14"/>
                    <measurement group_id="O4" value="0.31" spread="3.02"/>
                    <measurement group_id="O5" value="0.57" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio of week 1 to baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="2.60"/>
                    <measurement group_id="O2" value="0.52" spread="2.81"/>
                    <measurement group_id="O3" value="0.52" spread="2.54"/>
                    <measurement group_id="O4" value="0.55" spread="2.58"/>
                    <measurement group_id="O5" value="0.87" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events During Total Observation Time</title>
        <description>International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.
A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.
All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds (CRBE) and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).</description>
        <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O2">
            <title>75mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O3">
            <title>110mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O4">
            <title>150mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>26 week blinded treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events During Total Observation Time</title>
          <description>International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.
A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.
All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds (CRBE) and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="368"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="347"/>
                <count group_id="O5" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not clinically relevant bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Number of patients with possible clinically significant abnormalities. Clinically significant abnormalities refers to the increase or decrease from baseline.</description>
        <time_frame>6 month treatment period + 2 week post treatment follow up</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O2">
            <title>75mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O3">
            <title>110mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O4">
            <title>150mg Dabigatran Etexilate</title>
            <description>26 week blinded treatment</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>26 week blinded treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Number of patients with possible clinically significant abnormalities. Clinically significant abnormalities refers to the increase or decrease from baseline.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="368"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="347"/>
                <count group_id="O5" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST increase N=(359;359;388;329;356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST decrease N=(359;359;388;329;356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase N=(359;359;388;329;356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT decrease N=(359;359;388;329;356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increase N=(359;360;388;329;355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin decrease N=(359;360;388;329;355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 month treatment period + 3 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>50mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="E2">
          <title>75mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="E3">
          <title>110mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="E4">
          <title>150mg Dabigatran Etexilate</title>
          <description>26 week blinded treatment</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>26 week blinded treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="347"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>thrombocythaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="406"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>acute cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>acute LV failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>1st degree AV block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>congestive cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>LV failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>post infarct angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>reflux oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>erosive gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>non cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="406"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>acute cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>hydrocholecystis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacterial arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>infective cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>diabetic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>diverticuliitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>in stent coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>lead dislodgement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>haemoglobin decrease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>inadequate control of diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>cholesteatoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>small intestine carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>hemianopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>paraparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>angiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>BP fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>extremity necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

